December 20, 2022
December 20, 2022
Categories

The November/December 2022 News from ECOG-ACRIN blog is now available

Do you like it?
Read more
December 19, 2022
December 19, 2022
Categories

Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL

Do you like it?
Read more
December 15, 2022
December 15, 2022
Categories

Study E1910 consolidates the role of blinatumomab in acute lymphoblastic leukemia (ALL)

Do you like it?
Read more
December 14, 2022
December 14, 2022
Categories

Blinatumomab further improves survival among patients with B-ALL and a good prognosis (study E1910)

Do you like it?
Read more
December 13, 2022
December 13, 2022
Categories

Immunotherapy Plus Consolidation Chemo Improves Survival in B Lineage ALL

Do you like it?
Read more
December 13, 2022
December 13, 2022
Categories

HealthDay News informs the public of the 12-year TAILORx results

Do you like it?
Read more
December 13, 2022
December 13, 2022
Categories

Blinatumomab regimen may lead to ‘diminishing use of transplant’ for B-ALL subgroup (study E1910)

Do you like it?
Read more
December 13, 2022
December 13, 2022
Categories

Press Release: Practice-changing trial results for acute lymphoblastic leukemia (ALL)

Do you like it?
Read more
December 11, 2022
December 11, 2022
Categories

Press Release: A unique clinical trial leads to a dramatic decrease in early deaths from the rare and aggressive—yet highly curable—acute promyelocytic leukemia (APL)

Do you like it?
Read more
Load more
ECOG-ACRIN Cancer Research Group